These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20865334)

  • 1. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.
    Chakrapani A; Vellodi A; Robinson P; Jones S; Wraith JE
    J Inherit Metab Dis; 2010 Dec; 33(6):747-50. PubMed ID: 20865334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
    van Gelder CM; Poelman E; Plug I; Hoogeveen-Westerveld M; van der Beek NAME; Reuser AJJ; van der Ploeg AT
    J Inherit Metab Dis; 2016 May; 39(3):383-390. PubMed ID: 26768149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
    Kishnani PS; Nicolino M; Voit T; Rogers RC; Tsai AC; Waterson J; Herman GE; Amalfitano A; Thurberg BL; Richards S; Davison M; Corzo D; Chen YT
    J Pediatr; 2006 Jul; 149(1):89-97. PubMed ID: 16860134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
    J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.
    Kishnani PS; Corzo D; Leslie ND; Gruskin D; Van der Ploeg A; Clancy JP; Parini R; Morin G; Beck M; Bauer MS; Jokic M; Tsai CE; Tsai BW; Morgan C; O'Meara T; Richards S; Tsao EC; Mandel H
    Pediatr Res; 2009 Sep; 66(3):329-35. PubMed ID: 19542901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
    Nicolino M; Byrne B; Wraith JE; Leslie N; Mandel H; Freyer DR; Arnold GL; Pivnick EK; Ottinger CJ; Robinson PH; Loo JC; Smitka M; Jardine P; Tatò L; Chabrol B; McCandless S; Kimura S; Mehta L; Bali D; Skrinar A; Morgan C; Rangachari L; Corzo D; Kishnani PS
    Genet Med; 2009 Mar; 11(3):210-9. PubMed ID: 19287243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
    van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
    J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
    Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
    J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
    J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
    Ertoy Karagol HI; Inci A; Terece SP; Kilic A; Demir F; Yapar D; Koken G; Okur I; Ezgu FS; Tumer L; Bakirtas A;
    Int Arch Allergy Immunol; 2023; 184(4):370-375. PubMed ID: 36623499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.